Brian Koss
Overview
Explore the profile of Brian Koss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
925
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xia J, Zhao H, Edmondson J, Koss B, Zhan F
Trends Mol Med
. 2024 Aug;
31(1):79-93.
PMID: 39181803
Never in mitosis A (NIMA)-related kinase 2 (NEK2) is a serine/threonine kinase found in the nucleus and cytoplasm throughout the cell cycle. NEK2 is overexpressed in many cancers and is...
2.
Kelliher J, Folkerts M, Shen K, Song W, Tengler K, Stiefel C, et al.
Nat Commun
. 2024 May;
15(1):4634.
PMID: 38821984
The master DNA damage repair histone protein, H2AX, is essential for orchestrating the recruitment of downstream mediator and effector proteins at damaged chromatin. The phosphorylation of H2AX at S139, γH2AX,...
3.
Frett B, Stephens K, Koss B, Melnyk S, Farrar J, Saha D, et al.
Cancer Sci
. 2024 Jan;
115(3):963-973.
PMID: 38226414
Ectopic activation of rearranged during transfection (RET) has been reported to facilitate lineage differentiation and cell proliferation in different cytogenetic subtypes of acute myeloid leukemia (AML). Herein, we demonstrate that...
4.
Morehead L, Koss B, Fil D, Heflin B, Garg S, Wallis K, et al.
Mol Immunol
. 2023 Oct;
163:188-195.
PMID: 37837954
Immune checkpoint inhibitor therapy has drastically improved outcomes in treating cancer, particularly in melanoma. However, half of melanoma patients are resistant to treatment. One mechanism used by tumor cells to...
5.
Azevedo-Pouly A, Appell L, Burdine L, Rogers L, Morehead L, Fil D, et al.
Immunol Cell Biol
. 2023 May;
101(7):663-671.
PMID: 37149747
Modulation of T cell activity is an effective strategy for the treatment of autoimmune diseases, immune-related disorders and cancer. This highlights a critical need for the identification of proteins that...
6.
Roy Choudhury S, Heflin B, Taylor E, Koss B, Avaritt N, Tackett A
Cells
. 2023 Mar;
12(5).
PMID: 36899866
Overexpression of S100B is routinely used for disease-staging and for determining prognostic outcomes in patients with malignant melanoma. Intracellular interactions between S100B and wild-type (WT)-p53 have been demonstrated to limit...
7.
Guzman G, Reed M, Bielamowicz K, Koss B, Rodriguez A
Curr Oncol Rep
. 2023 Feb;
25(5):479-489.
PMID: 36853475
Purpose Of Review: This review will discuss the challenges facing chimeric antigen receptor (CAR)-T cell application for solid tumors and opportunities to overcome these obstacles. In addition, this review will...
8.
Koss B, Shields B, Taylor E, Storey A, Byrum S, Gies A, et al.
Cancer Res
. 2020 Oct;
80(21):4707-4719.
PMID: 33004350
T-cell exhaustion in cancer is linked to poor clinical outcomes, where evidence suggests T-cell metabolic changes precede functional exhaustion. Direct competition between tumor-infiltrating lymphocytes (TIL) and cancer cells for metabolic...
9.
Trentzsch M, Nyamugenda E, Miles T, Griffin H, Russell S, Koss B, et al.
Cell Death Discov
. 2020 Mar;
6:8.
PMID: 32123584
Genetic obesity increases in liver phosphatidylcholine (PC)/phosphatidylethanolamine (PE) ratio, inducing endoplasmic reticulum (ER) stress without concomitant increase of ER chaperones. Here, it is found that exposing mice to a palm...
10.
Taylor E, Koss B, Davis L, Tackett A
Methods Mol Biol
. 2019 Sep;
2055:213-228.
PMID: 31502154
Recent advances in immunotherapy have revolutionized the treatment of certain cancers. Some patients show a durable response to these immunotherapies, while others show little benefit or develop resistance. Identification of...